Andira CEO Dana Lambert, PhD says, “I wanted to take the opportunity to recognize Dr. Claudia Dietrich and her outstanding achievements as a research scientist on our team. She is a talented and highly motivated professional and has been a driving force behind the successful development of our wound care products to date.”
Dr. Dietrich is a native of Brazil. In 2007, she graduated with a Bachelor of Dental Surgery (DDS) and quickly decided to pursue a master’s degree in oral science and biomaterials. While getting her master’s degree, Dr. Dietrich took over her father’s dental practice simultaneously working as a full-time dentist and full-time student. She moved to Vancouver in 2017, for a post-doctoral fellowship at the University of British Columbia following her PhD program completed in Brazil in Dentistry with an emphasis in biomaterials.
At the beginning of her career, Dr. Dietrich’s goal was to be a professor. However, after a series of exciting research projects with significant potential were shelved and never advanced into commercial development, Dr. Dietrich began looking for opportunities where she could combine a passion for research and the opportunity to commercialize new products.
When asked about why she works at Andira, Dr. Dietrich explained, “I want to work in applied research that directly addresses the market needs, and in the development of products that will reach a wider audience and really help people. It is important to me to see the pioneering work we are doing at Andira be commercialized.” Dr. Dietrich has optimized the concentrations and dosing of Andira’s wound care products and arrived at the commercial formula to be presented to FDA this year.
Dr. Lambert explains the significance of Dr. Dietrich’s contribution, “Gram negatives are generally the hardest bacteria to treat. Dr. Dietrich has been successful in killing gram negatives and significantly increased the efficacy of our topical wound care products not only greatly increasing the number of bugs it kills but also increasing the kill rate, facilitating important development milestones critical for regulatory approvals and patient outcomes. To achieve these milestones, Dr. Dietrich had to develop a series of complex research models which were required to arrive at our formulas. Her work has been nothing short of extraordinary.”
Dr. Dietrich concludes, “We don’t have time to lose doing things that don’t make us happy. Conducting research and product development for Andira is immensely satisfying knowing we are solving problems in medicine that will make a real difference in the lives of those in need.”
